MARKHAM, Ontario, Sept. 15, 2017 -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common Share”) for the month of September 2017, which is payable on October 16, 2017 to shareholders of record at the close of business on September 29, 2017. This dividend is designated as an “eligible dividend” within the meaning of the Income Tax Act (Canada).
Extendicare has a Dividend Reinvestment Plan (the “DRIP”), which provides Canadian resident holders of Common Shares with the opportunity to increase their respective investments at a 3% discount to the volume weighted average trading price of the Common Shares on the TSX for the five trading days immediately preceding the dividend payment date. A copy of the DRIP package is available under the investors section of Extendicare’s website.
ABOUT EXTENDICARE
Extendicare is a leading provider of care and services for seniors throughout Canada. Through our network of 114 operated senior care and living centres (65 owned/49 managed), as well as our home health care operations, we are committed to delivering care throughout the health care continuum to meet the needs of a growing seniors’ population in Canada. Our qualified and highly trained workforce of 23,800 individuals is dedicated to helping people live better through a commitment to quality service and a passion for what we do.
Forward-looking Statements
Information provided by Extendicare from time to time, including this release, contains or may contain forward-looking statements concerning anticipated financial events, results, circumstances, economic performance or expectations with respect to Extendicare and its subsidiaries, including, without limitation, statements regarding its business operations, business strategy, and financial condition. Forward-looking statements can be identified because they generally contain the words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “objective”, “plan”, “project”, “will” or other similar expressions or the negative thereof. Forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available, and Extendicare assumes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Extendicare to differ materially from those expressed or implied in the statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on Extendicare’s forward-looking statements. Further information can be found in the disclosure documents filed by Extendicare with the securities regulatory authorities, available at www.sedar.com and on Extendicare’s website at www.extendicare.com.
For further information, contact:
Jillian E. Fountain
Corporate Secretary
Phone: (905) 470-5534; Fax: (905) 470-4003
Email: [email protected]
www.extendicare.com


Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Britain Courts Anthropic Amid US Defense Department Dispute
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
First Western Ship Transits Strait of Hormuz Since Iran War Began
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 



